These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17016822)

  • 1. No major impact of mammography screening on the age specific incidence rates of breast cancer in the Netherlands.
    Verkooijen HM; Fioretta G; van der Heiden M; Koot VC; Bouchardy C
    Int J Cancer; 2006 Dec; 119(12):2988; author reply 2989-90. PubMed ID: 17016822
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations.
    Verkooijen HM; Koot VC; Fioretta G; van der Heiden M; Schipper ME; Rapiti E; Peeters PH; Peterse JL; Bouchardy C
    Breast Cancer Res Treat; 2008 Feb; 107(3):389-95. PubMed ID: 17431760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality reduction by breast-cancer screening.
    Bonneux L
    Lancet; 2003 Jul; 362(9379):245. PubMed ID: 12885491
    [No Abstract]   [Full Text] [Related]  

  • 4. [Screening for breast cancer after the age of 70: effect on breast cancer mortality].
    van Dijck JA; Verbeek AL; Hendriks JH; Holland R
    Ned Tijdschr Geneeskd; 1995 Mar; 139(9):428-33. PubMed ID: 7891764
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammography and the value of screening.
    Whitehouse GH
    Br J Hosp Med; 1985 Nov; 34(5):263. PubMed ID: 3836718
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mass screening for breast cancer in women younger than 50 years; a literature review of the anticipated effect on mortality].
    Peer PG; Verbeek AL
    Ned Tijdschr Geneeskd; 1991 Apr; 135(15):651-5. PubMed ID: 2038380
    [No Abstract]   [Full Text] [Related]  

  • 8. Screening caused rising incidence rates of ductal carcinoma in situ of the breast.
    van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
    Breast Cancer Res Treat; 2009 May; 115(1):181-3. PubMed ID: 18516674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness analysis of breast cancer screening with mammography].
    Iinuma T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():226-8. PubMed ID: 17682158
    [No Abstract]   [Full Text] [Related]  

  • 10. Mammographic screening of women aged 40 to 49 years. Is it justified?
    Feig SA
    Obstet Gynecol Clin North Am; 1994 Dec; 21(4):587-606. PubMed ID: 7731636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40-49 years.
    Taylor R; Page A; Bampton D; Estoesta J; Rickard M
    J Med Screen; 2004; 11(4):199-206. PubMed ID: 15563775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological changes in breast tumours in Italy: the IMPACT study on mammographic screening programmes.
    IMPACT WORKING Group
    Pathologica; 2011 Oct; 103(5):290-3. PubMed ID: 22393684
    [No Abstract]   [Full Text] [Related]  

  • 13. Breast cancer trends: opportunistic screening in Austria versus controlled screening in Finland and Sweden.
    Vutuc C; Waldhoer T; Haidinger G
    Eur J Cancer Prev; 2006 Aug; 15(4):343-6. PubMed ID: 16835504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography.
    Morrell S; Barratt A; Irwig L; Howard K; Biesheuvel C; Armstrong B
    Cancer Causes Control; 2010 Feb; 21(2):275-82. PubMed ID: 19894130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contributions of the epidemiological cancer registries to the evaluation of mammography screening in Germany].
    Urbschat I; Kieschke J; Schlanstedt-Jahn U; von Gehlen S; Thiel A; Jensch P
    Gesundheitswesen; 2005 Jul; 67(7):448-54. PubMed ID: 16103967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinically occult breast cancer. Screening and preoperative marking].
    Kubista E; Adler A; Seifert M; Wolf G
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():82-4. PubMed ID: 8118369
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study.
    Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Distressed or relieved? Psychological sequelae of breast cancer screening in Netherlands].
    van Wijngaarden DA
    Ned Tijdschr Geneeskd; 1999 Apr; 143(16):873-4. PubMed ID: 10347659
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
    Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
    Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Breast neoplasms in Italy and Sicily].
    Crocetti E; Buzzoni C; Puliti D
    Epidemiol Prev; 2009; 33(1-2 Suppl 1):87-94. PubMed ID: 19621568
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.